The novel coronavirus SARS-Cov-2 infection which started as a cluster of viral pneumonia cases in Wuhan, China has rapidly spread globally though human-to-human transmission leading to a global pandemic. The causative coronavirus is structurally related to SARS coronavirus. The spike (S) protein on the virus binds to human ACE-2 receptor leading to viral entry into cell and infectivity. Most of the affected individual are either asymptomatic or experience a mild viral illness. However, a minority of patients have a complicated course with respiratory failure, ARDS and multiorgan failure leading to death, especially in those with advanced age or comorbidities. The diagnosis of COVIS-19 is by RT-PCR test on nasopharyngeal or oropharyngeal swab. Serologic tests are under development. Many antiviral medicines are currently under trial including hydroxychloroquine, remdesivir, lopinovir and ivermectin. The immune therapy options under trial include convalescent plasma, high dose intravenous immunoglobulins (IVIG) and anti-IL6 monoclonal antibody tocilizumab. Multiple trials are also underway to develop a vaccine to control this global pandemic. Various current potential targets include regions of the S protein.
SARS – Cov – 2, Clinical Syndrome, Pneumonia